S&P 500   3,972.05 (+1.81%)
DOW   31,912.60 (+2.08%)
QQQ   291.94 (+1.13%)
AAPL   142.21 (+3.36%)
MSFT   259.64 (+2.80%)
FB   194.83 (+0.67%)
GOOGL   2,224.64 (+2.13%)
AMZN   2,110.87 (-1.90%)
TSLA   662.10 (-0.27%)
NVDA   165.58 (-0.81%)
BABA   86.79 (-0.18%)
NIO   15.78 (-4.01%)
AMD   93.55 (+0.05%)
CGC   5.17 (-6.34%)
MU   69.21 (+0.45%)
T   20.84 (+2.16%)
GE   75.88 (+0.84%)
F   12.82 (+2.56%)
DIS   104.86 (+2.38%)
AMC   11.58 (-3.74%)
PFE   52.95 (+0.91%)
PYPL   81.10 (+0.70%)
NFLX   184.24 (-1.13%)
S&P 500   3,972.05 (+1.81%)
DOW   31,912.60 (+2.08%)
QQQ   291.94 (+1.13%)
AAPL   142.21 (+3.36%)
MSFT   259.64 (+2.80%)
FB   194.83 (+0.67%)
GOOGL   2,224.64 (+2.13%)
AMZN   2,110.87 (-1.90%)
TSLA   662.10 (-0.27%)
NVDA   165.58 (-0.81%)
BABA   86.79 (-0.18%)
NIO   15.78 (-4.01%)
AMD   93.55 (+0.05%)
CGC   5.17 (-6.34%)
MU   69.21 (+0.45%)
T   20.84 (+2.16%)
GE   75.88 (+0.84%)
F   12.82 (+2.56%)
DIS   104.86 (+2.38%)
AMC   11.58 (-3.74%)
PFE   52.95 (+0.91%)
PYPL   81.10 (+0.70%)
NFLX   184.24 (-1.13%)
S&P 500   3,972.05 (+1.81%)
DOW   31,912.60 (+2.08%)
QQQ   291.94 (+1.13%)
AAPL   142.21 (+3.36%)
MSFT   259.64 (+2.80%)
FB   194.83 (+0.67%)
GOOGL   2,224.64 (+2.13%)
AMZN   2,110.87 (-1.90%)
TSLA   662.10 (-0.27%)
NVDA   165.58 (-0.81%)
BABA   86.79 (-0.18%)
NIO   15.78 (-4.01%)
AMD   93.55 (+0.05%)
CGC   5.17 (-6.34%)
MU   69.21 (+0.45%)
T   20.84 (+2.16%)
GE   75.88 (+0.84%)
F   12.82 (+2.56%)
DIS   104.86 (+2.38%)
AMC   11.58 (-3.74%)
PFE   52.95 (+0.91%)
PYPL   81.10 (+0.70%)
NFLX   184.24 (-1.13%)
S&P 500   3,972.05 (+1.81%)
DOW   31,912.60 (+2.08%)
QQQ   291.94 (+1.13%)
AAPL   142.21 (+3.36%)
MSFT   259.64 (+2.80%)
FB   194.83 (+0.67%)
GOOGL   2,224.64 (+2.13%)
AMZN   2,110.87 (-1.90%)
TSLA   662.10 (-0.27%)
NVDA   165.58 (-0.81%)
BABA   86.79 (-0.18%)
NIO   15.78 (-4.01%)
AMD   93.55 (+0.05%)
CGC   5.17 (-6.34%)
MU   69.21 (+0.45%)
T   20.84 (+2.16%)
GE   75.88 (+0.84%)
F   12.82 (+2.56%)
DIS   104.86 (+2.38%)
AMC   11.58 (-3.74%)
PFE   52.95 (+0.91%)
PYPL   81.10 (+0.70%)
NFLX   184.24 (-1.13%)
FRA:FRE

Fresenius SE & Co. KGaA (FRE) Stock Forecast, Price & News

€32.31
-0.47 (-1.43%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
€31.80
€32.48
50-Day Range
€31.18
€35.13
52-Week Range
€60.16
€80.00
Volume
1.08 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive FRE News and Ratings via Email

Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter.

Fresenius SE & Co. KGaA logo

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical Care Facilities
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
316,078
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.58 out of 5 stars

Analyst Opinion: 3.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Fresenius SE & Co. KGaA (FRA:FRE) Frequently Asked Questions

Is Fresenius SE & Co. KGaA a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fresenius SE & Co. KGaA in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fresenius SE & Co. KGaA stock.
View analyst ratings for Fresenius SE & Co. KGaA
or view top-rated stocks.

What price target have analysts set for FRE?

2 brokerages have issued 1-year price targets for Fresenius SE & Co. KGaA's stock. Their forecasts range from €30.00 to €60.25. On average, they expect Fresenius SE & Co. KGaA's stock price to reach €43.31 in the next year. This suggests a possible upside of 34.0% from the stock's current price.
View analysts' price targets for Fresenius SE & Co. KGaA
or view top-rated stocks among Wall Street analysts.

Who are Fresenius SE & Co. KGaA's key executives?
Fresenius SE & Co. KGaA's management team includes the following people:
  • Mr. Stephan Sturm, CEO, Pres & Chairman of Management Board - Fresenius Management SE (Age 59, Pay $3.81M)
  • Ms. Rachel Clare Empey, CFO & Member of Management Board - Fresenius Management SE (Age 46, Pay $2.14M)
  • Dr. Francesco De Meo, Member of Management Board - Fresenius Management SE (Age 59, Pay $2.35M)
  • Dr. Ernst Wastler, Member of Management Board - Fresenius Management SE (Age 64, Pay $1.8M)
  • Mr. Rice Powell, Member of Management Board - Fresenius Management SE (Age 67, Pay $3.82M)
  • Dr. Sebastian Biedenkopf, Chief Legal Officer, HR, Labor Relations Director, Risk Mgmt & Member of Mgmt. Board (Age 57, Pay $1.51M)
  • Mr. Michael Sen, Member of Management Board (Age 54, Pay $2.23M)
  • Mr. Markus Georgi, Sr. VP of Investor Relations
What other stocks do shareholders of Fresenius SE & Co. KGaA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fresenius SE & Co. KGaA investors own include Illumina (ILMN), Daimler (DAI), Endologix (ELGX), Allianz (ALV), APA (APA), Cambrex (CBM), Linde (LIN), Alibaba Group (BABA), General Electric (GE) and HeidelbergCement (HEI).

What is Fresenius SE & Co. KGaA's stock symbol?

Fresenius SE & Co. KGaA trades on the FRA under the ticker symbol "FRE."

What is Fresenius SE & Co. KGaA's stock price today?

One share of FRE stock can currently be purchased for approximately €32.31.

How many employees does Fresenius SE & Co. KGaA have?

Fresenius SE & Co. KGaA employs 316,078 workers across the globe.

What is Fresenius SE & Co. KGaA's official website?

The official website for Fresenius SE & Co. KGaA is www.fresenius.de.

How can I contact Fresenius SE & Co. KGaA?

Fresenius SE & Co. KGaA's mailing address is Else-Kroener-Str. 1, BAD HOMBURG VOR DER HOEHE, 61352, Germany. The company can be reached via phone at +49-6172-6080.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.